Related Experiment Videos
Hyaluronan synthase expression in ovarian cancer
Hiromitsu Yabushita1, Mari Noguchi, Tameko Kishida
1Department of Obstetrics and Gynecology, School of Medicine, Aichi Medical University, Aichi 480-1195, Japan. yab@aichi-med-u-ac.jp
Oncology Reports
|September 18, 2004
Summary
Hyaluronan synthase 1 (HAS1) expression in ovarian cancer correlates with increased angiogenesis and poorer patient survival, suggesting it may drive disease progression. HAS1 is an independent predictor of survival in ovarian cancer patients.
Area of Science:
- Oncology
- Biochemistry
- Pathology
Background:
- Hyaluronan synthases (HAS) are enzymes responsible for hyaluronan biosynthesis.
- Hyaluronan plays a role in cell proliferation, migration, and angiogenesis.
- The role of HAS expression in ovarian carcinoma remains unclear.
Purpose of the Study:
- To investigate the correlation between immunohistochemical expression of hyaluronan synthases (HAS1, HAS2, HAS3) and clinicopathological features or clinical outcomes in ovarian cancer.
- To assess the relationship between HAS expression, CD44 expression, microvessel density, and patient survival.
Main Methods:
- Tumor tissue sections from 33 ovarian cancer patients were analyzed using immunohistochemistry for HAS1, HAS2, HAS3, and CD44.
- Positive expression was defined as intense staining in >50% of tumor cells.
- Microvessel density was quantified under light microscopy.
Main Results:
- HAS1 expression was observed in 12 cases, HAS2 in 21, and HAS3 in 11.
- HAS1 expression was associated with higher microvessel density and more frequent CD44 expression.
- Overall survival was shorter in HAS1-positive patients compared to HAS1-negative patients.
Conclusions:
- HAS1 expression in ovarian cancer may be linked to disease progression via angiogenesis.
- HAS1 expression appears to be an independent predictor of patient survival in ovarian carcinoma.
- HAS2 and HAS3 expression did not show significant correlations with clinicopathological factors or survival outcomes.